Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Zoran, Popmihajlov"'
Autor:
Paul W Noble, Luca Richeldi, David A Lynch, Steven Greenberg, THEODORE F REISS, Zoran Popmihajlov, Donna J Sutherland, Gerald S Horan, Atalanta Ghosh
Publikováno v:
BMJ Open Respiratory Research, Vol 9, Iss 1 (2022)
Externí odkaz:
https://doaj.org/article/c353a750d53f4c1784f7d28572dde2a9
Autor:
Zoran Popmihajlov, Lei Pang, Elizabeth Brown, Amita Joshi, Shu-Chih Su, Susan S. Kaplan, English D. Willis
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 14, Iss 12, Pp 2916-2920 (2018)
Background: ZOSTAVAX (ZVL; Zoster Virus Live), is a single dose, live, attenuated vaccine licensed for the prevention of herpes zoster (HZ) and post herpetic neuralgia (PHN) in adults ≥50 years of age. Injection site adverse events (AEs) of erythem
Externí odkaz:
https://doaj.org/article/d2d8d022df1c4b4285f5b3bb7cd593d2
Autor:
Myron J. Levin, Eddy Bresnitz, Zoran Popmihajlov, Adriana Weinberg, Kai-Li Liaw, English Willis, Jeffrey R. Curtis
Publikováno v:
Expert Review of Vaccines, Vol 16, Iss 12, Pp 1217-1230 (2017)
Introduction: The active component of the herpes zoster vaccine (ZVL), licensed for people ≥50 years of age, is a live attenuated varicella-zoster virus. ZVL is contraindicated for immune compromised individuals, with limited regard to the degree o
Externí odkaz:
https://doaj.org/article/667c6e4635824d279235767150acf89f
Autor:
Zoran Popmihajlov, Michael Boeckh, Lei Pang, Drew J. Winston, Kimberly Hurtado, Vicki A. Morrison, Luis H. Camacho, Jessie Durrand Hall, Shu-Chih Su, Kathleen M. Mullane, Ann M. Arvin, Paula W. Annunziato, Susan S. Kaplan
Publikováno v:
Open Forum Infectious Diseases
Background In phase 3 trials, inactivated varicella zoster virus (VZV) vaccine (ZVIN) was well tolerated and efficacious against herpes zoster (HZ) in autologous hematopoietic stem cell transplant (auto-HSCT) recipients and patients with solid tumor
Autor:
Myron J. Levin, Adriana Tovar Salazar, Lei Pang, Jennifer Canniff, Barbara J. McCarson, Kenneth E. Schmader, Yupanqui Caldas, Zoran Popmihajlov, Adriana Weinberg, Michael J Johnson, Jason C. Martin
Publikováno v:
The Journal of Infectious Diseases. 219:335-338
Protection against zoster conferred by zoster vaccine live (ZVL; Zostavax) wanes over time. We compared varicella-zoster virus cell-mediated immunity (VZV-CMI) of adults ≥70 years who received a second dose of ZVL ≥10 years after the initial dose
Autor:
Zoran Popmihajlov, Kendall A Smith
Publikováno v:
PLoS ONE, Vol 3, Iss 2, p e1581 (2008)
As interleukin-2 (IL2) is central to the clonal expansion of antigen-selected T cells, we investigated the relationship between IL2 and the negative regulatory transcription factor FOXP3. We found IL2 to be responsible for T cell antigen receptor (TC
Externí odkaz:
https://doaj.org/article/bda6d49843fa48bf987aeb9fee9e91ab
Autor:
Patricia Saddier, Meredith Woodward, English D. Willis, Paula W. Annunziato, Zoran Popmihajlov, Elizabeth Brown, Anne A. Gershon, Neal A. Halsey
Publikováno v:
Vaccine. 35:7231-7239
Zoster vaccine is a single dose live, attenuated vaccine (ZVL) indicated for individuals ≥50 years-old for the prevention of herpes zoster (HZ). Safety data from clinical trials and post-licensure studies provided reassurance that ZVL is generally
Autor:
Jennifer Canniff, Myron J. Levin, Kenneth E. Schmader, Yupanqui Caldas, Zoran Popmihajlov, Lei Pang, Michael J Johnson, Adriana Weinberg, Alice Cho, Adriana Tovar-Salazar
Publikováno v:
Journal of Virology. 93
Older age is associated with increased infectious morbidity and decreased immune responses to vaccines, but the mechanisms that mediate this effect are incompletely understood. The efficacy and immunogenicity of the live attenuated zoster vaccine (ZV
Autor:
Yiling Jiang, Matthias Hunger, Zoran Popmihajlov, Robyn Thorén, Jennifer Eriksson, Francois Bourhis, Lynn Finelli
Objectives: Immunocompromised subjects are at increased risk for herpes zoster (HZ) and HZ-related complications, such as post-herpetic neuralgia (PHN). We describe health utilities, health care resource utilization (HCRU), productivity loss and heal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46ca2da1216cd9478aaeb922f81a3434
Autor:
Kathleen M Mullane, Vicki A Morrison, Luis H Camacho, Ann Arvin, Shelly A McNeil, Jessie Durrand, Bernadette Campbell, Shu-Chih Su, Ivan S F Chan, Janie Parrino, Susan S Kaplan, Zoran Popmihajlov, Paula W Annunziato, S Cerana, MO Dictar, P Bonvehi, JP Tregnaghi, L Fein, D Ashley, M Singh, T Hayes, G Playford, O Morrissey, J Thaler, T Kuehr, R Greil, M Pecherstorfer, L Duck, K Van Eygen, M Aoun, B De Prijck, FA Franke, CHE Barrios, AVA Mendes, SV Serrano, RF Garcia, F Moore, JFC Camargo, LA Pires, RS Alves, A Radinov, K Oreshkov, V Minchev, AI Hubenova, T Koynova, I Ivanov, B Rabotilova, PA Petrov, P Chilingirov, S Karanikolov, J Raynov, D Grimard, S McNeil, D Kumar, LM Larratt, K Weiss, R Delage, FJ Diaz-Mitoma, PO Cano, F Couture, P Carvajal, A Yepes, R Torres Ulloa, P Fardella, C Caglevic, C Rojas, E Orellana, P Gonzalez, A Acevedo, KM Galvez, ME Gonzalez, S Franco, JG Restrepo, CA Rojas, C Bonilla, LE Florez, AV Ospina, R Manneh, R Zorica, DV Vrdoljak, M Samarzija, L Petruzelka, J Vydra, J Mayer, D Cibula, J Prausova, G Paulson, M Ontaneda, K Palk, A Vahlberg, R Rooneem, F Galtier, D Postil, F Lucht, F Laine, O Launay, H Laurichesse, X Duval, OA Cornely, B Camerer, J Panse, M Zaiss, H-G Derigs, H Menzel, M Verbeek, V Georgoulias, D Mavroudis, A Anagnostopoulos, E Terpos, D Cortes, J Umanzor, S Bejarano, RW Galeano, RSM Wong, P Hui, P Pedrazzoli, L Ruggeri, F Aversa, A Bosi, G Gentile, A Rambaldi, A Contu, L Marei, A Abbadi, W Hayajneh, J Kattan, F Farhat, G Chahine, J Rutkauskiene, LJ Marfil Rivera, YA Lopez Chuken, H Franco Villarreal, J Lopez Hernandez, H Blacklock, RI Lopez, R Alvarez, AM Gomez, TS Quintana, MDC Moreno Larrea, SJ Zorrilla, E Alarcon, FCA Samanez, PB Caguioa, BJ Tiangco, EM Mora, RD Betancourt-Garcia, D Hallman-Navarro, LJ Feliciano-Lopez, HA Velez-Cortes, F Cabanillas, DE Ganea, TE Ciuleanu, DG Ghizdavescu, L Miron, CL Cebotaru, CI Cainap, R Anghel, MV Dvorkin, OA Gladkov, NV Fadeeva, AA Kuzmin, ON Lipatov, II Zbarskaya, FS Akhmetzyanov, IV Litvinov, BV Afanasyev, M Cherenkova, D Lioznov, IA Lisukov, YA Smirnova, S Kolomietz, H Halawani, YT Goh, L Drgona, J Chudej, M Matejkova, M Reckova, BL Rapoport, WM Szpak, DR Malan, N Jonas, CW Jung, DG Lee, SS Yoon, J Lopez Jimenez, I Duran Martinez, JF Rodriguez Moreno, C Solano Vercet, R de la Camara, M Batlle Massana, S-P Yeh, C-Y Chen, H-H Chou, C-M Tsai, C-H Chiu, N Siritanaratkul, L Norasetthada, V Sriuranpong, K Seetalarom, H Akan, F Dane, MA Ozcan, GH Ozsan, SF Kalayoglu Besisik, A Cagatay, S Yalcin, A Peniket, SR Mullan, KM Dakhil, K Sivarajan, JJ-G Suh, A Sehgal, F Marquez, EG Gomez, MR Mullane, WL Skinner, RJ Behrens, DR Trevarthe, MA Mazurczak, EA Lambiase, CA Vidal, SY Anac, GA Rodrigues, B Baltz, R Boccia, MS Wertheim, CS Holladay, D Zenk, W Fusselman, JL Wade III, AJ Jaslowsk, J Keegan, MO Robinson, RS Go, J Farnen, B Amin, D Jurgens, GF Risi, PG Beatty, T Naqvi, S Parshad, VL Hansen, M Ahmed, PD Steen, S Badarinath, A Dekker, MA Scouros, DE Young, W Graydon Harker, SD Kendall, ML Citron, S Chedid, JG Posada, MK Gupta, S Rafiyath, J Buechler-Price, S Sreenivasappa, CH Chay, JM Burke, SE Young, A Mahmood, JW Kugler, G Gerstner, J Fuloria, ND Belman, R Geller, J Nieva, BP Whittenberger, BMY Wong, TP Cescon, G Abesada-Terk, MJ Guarino, A Zweibach, EN Ibrahim, G Takahashi, MA Garrison, RB Mowat, BS Choi, IA Oliff, J Singh, KA Guter, K Ayrons, KM Rowland, SJ Noga, SB Rao, A Columbie, MT Nualart, GR Cecchi, LT Campos, M Mohebtash, MR Flores, R Rothstein-Rubin, BM O'Connor, G Soori, M Knapp, FG Miranda, BW Goodgame, M Kassem, R Belani, S Sharma, T Ortiz, HL Sonneborn, AB Markowitz, D Wilbur, E Meiri, VS Koo, HS Jhangiani, L Wong, S Sanani, SJ Lawrence, CM Jones, C Murray, C Papageorgiou, JS Gurtler, JL Ascensao, ML Venigalla, M D'Andrea, C De Las Casas, DJ Haile, FU Qazi, JL Santander, MR Thomas, VP Rao, M Craig, RJ Garg, R Robles, RM Lyons, RK Stegemoller, S Goel, S Garg, P Lowry, C Lynch, B Lash, T Repka, J Baker, BS Goueli, TC Campbell, DA Van Echo, YJ Lee, EA Reyes, FM Senecal, G Donnelly, P Byeff, R Weiss, T Reid, E Roeland, A Goel, DM Prow, DS Brandt, HG Kaplan, JE Payne, MG Boeckh, PJ Rosen, RR Mena, R Khan, RF Betts, SA Sharp, VA Morrison, D Fitz-Patrick, J Congdon, N Erickson, R Abbasi, S Henderson, A Mehdi, EJ Wos, E Rehmus, L Beltzer, RA Tamayo, T Mahmood, AC Reboli, A Moore, JM Brown, J Cruz, DP Quick, JL Potz, KW Kotz, M Hutchins, NM Chowhan, YD Devabhaktuni, P Braly, RA Berenguer, SC Shambaugh, TJ O'Rourke, WA Conkright, CF Winkler, FEK Addo, JP Duic, KP High, ME Kutner, R Collins, DR Carrizosa, DJ Perry, E Kailath, N Rosen, R Sotolongo, S Shoham, T Chen
Summary Background Patients who are immunocompromised because of malignancy have an increased risk of herpes zoster and herpes zoster-related complications. We aimed to investigate the efficacy and safety of an inactivated varicella zoster virus (VZV
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9512b960de076ec44f04d635a16f9143
http://hdl.handle.net/11573/1331005
http://hdl.handle.net/11573/1331005